Who
John M. Wesolowski
Principal Accounting Officer
Company insider
Files Form 4 as: Principal Accounting Officer, Intensity Therapeutics.
In numbers
- Trades disclosed
- 14
- Buys
- 0
- Sells
- 0
- Bought
- $0
- Sold
- $0
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 19 Jul 2023
- Last trade
- 16 Jul 2026
- Last filed
- 20 Jul 2026
Companies traded
Activity over time
Not enough dated trades to draw.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 16 Jul 2026filed 20 Jul 2026 | INTS Intensity Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —11,000 at $0.00 | filing |
| 16 Jul 2026filed 20 Jul 2026 | INTS Intensity Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —11,000 at $0.00 | filing |
| 30 Jun 2026filed 1 Jul 2026 | INTS Intensity TherapeuticsBiotechnology | SEC FORM 4 Code A | $13K3,688 at $3.49 | filing |
| 30 Jun 2026filed 1 Jul 2026 | INTS Intensity TherapeuticsBiotechnology | SEC FORM 4 Code A | $13K3,688 at $3.49 | filing |
| 31 Dec 2025filed 5 Jan 2026 | INTS Intensity TherapeuticsBiotechnology | SEC FORM 4 Code A | $2,3378,918 at $0.262 | filing |
| 31 Dec 2025filed 5 Jan 2026 | INTS Intensity TherapeuticsBiotechnology | SEC FORM 4 Code A | $2,3198,918 at $0.26 | filing |
| 30 Jun 2025filed 2 Jul 2025 | INTS Intensity TherapeuticsBiotechnology | SEC FORM 4 Code A | $18K69,745 at $0.26 | filing |
| 2 May 2025filed 6 May 2025 | INTS Intensity Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —100,000 at $0.00 | filing |
| 2 May 2025filed 6 May 2025 | INTS Intensity Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —100,000 at $0.00 | filing |
| 21 Oct 2024filed 23 Oct 2024 | INTS Intensity Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —70,028 at $0.00 | filing |
| 5 Jun 2024filed 7 Jun 2024 | INTS Intensity Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —1,000 at $0.00 | filing |
| 5 Jun 2024filed 7 Jun 2024 | INTS Intensity TherapeuticsBiotechnology | SEC FORM 4 Code M | $4,0001,000 at $4.00 | filing |
| 6 Mar 2024filed 7 Mar 2024 | INTS Intensity Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —25,000 at $0.00 | filing |
| 19 Jul 2023filed 21 Jul 2023 | INTS Intensity Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.
Sectors
No trade we could place in a sector.